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Abstract: In search of novel genes associated with glioma pathogenesis, we have previously shown fre-
quent deletions of the KIAA1797/FOCAD gene in malignant gliomas, and a tumor suppressor function
of the encoded focadhesin impacting proliferation and migration of glioma cells in vitro and in vivo.
Here, we examined an association of reduced FOCAD gene copy number with overall survival of patients
with astrocytic gliomas, and addressed the molecular mechanisms that govern the suppressive effect of
focadhesin on glioma growth. FOCAD loss was associated with inferior outcome in patients with isoci-
trate dehydrogenase 1 or 2 (IDH)-mutant astrocytic gliomas of WHO grades II-IV. Multivariate analysis
considering age at diagnosis as well as IDH mutation, MGMT promoter methylation, and CDKN2A/B ho-
mozygous deletion status confirmed reduced FOCAD gene copy number as a prognostic factor for overall
survival. Using a yeast two-hybrid screen and pull-down assays, tubulin beta-6 and other tubulin family
members were identified as novel focadhesin-interacting partners. Tubulins and focadhesin co-localized
to centrosomes where focadhesin was enriched in proximity to centrioles. Focadhesin was recruited to
microtubules via its interaction partner SLAIN motif family member 2 and reduced microtubule assem-
bly rates, possibly explaining the focadhesin-dependent decrease in cell migration. During the cell cycle,
focadhesin levels peaked in G2/M phase and influenced time-dependent G2/M progression potentially via
polo like kinase 1 phosphorylation, providing a possible explanation for focadhesin-dependent cell growth
reduction. We conclude that FOCAD loss may promote biological aggressiveness and worsen clinical
outcome of diffuse astrocytic gliomas by enhancing microtubule assembly and accelerating G2/M phase
progression.
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Abstract 
In search of novel genes associated with glioma pathogenesis, we have previously shown 
frequent deletions of the KIAA1797/FOCAD gene in malignant gliomas, and a tumor 
suppressor function of the encoded focadhesin impacting proliferation and migration of 
glioma cells in vitro and in vivo. Here, we examined an association of diminished FOCAD 
copy number with overall survival of patients with astrocytic gliomas, and addressed the 
molecular mechanisms that govern the suppressive effect of focadhesin on glioma growth. 
FOCAD loss was associated with inferior outcome in patients with isocitrate dehydrogenase 
1 or 2 (IDH)-mutant astrocytic gliomas of WHO grades II-IV. Multivariate analysis considering 
age at diagnosis as well as IDH mutation, MGMT promoter methylation, and CDKN2A/B 
homozygous deletion status confirmed FOCAD loss as a prognostic factor for overall 
survival. Using a yeast two-hybrid screen and pull-down assays, tubulin beta-6 and other 
tubulin family members were identified as novel focadhesin-interacting partners. Tubulins 
and focadhesin co-localized to centrosomes where focadhesin was enriched in proximity to 
centrioles. Focadhesin was recruited to microtubules via its interaction partner SLAIN motif 
family member 2 and reduced microtubule assembly rates, possibly explaining the 
focadhesin-dependent decrease in cell migration. During the cell cycle, focadhesin levels 
peaked in G2/M phase and influenced time-dependent G2/M progression potentially via polo 
like kinase 1 phosphorylation, providing a possible explanation for focadhesin-dependent cell 
growth reduction. We conclude that FOCAD loss may promote biological aggressiveness 
and worsen clinical outcome of diffuse astrocytic gliomas by enhancing microtubule 
assembly and accelerating G2/M phase progression. 
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Introduction 
Diffuse astrocytic gliomas are diffusely infiltrating brain tumors classified by the World Health 
Organization (WHO) as diffuse astrocytoma (WHO grade II), anaplastic astrocytoma (WHO 
grade III), and glioblastoma (WHO grade IV) based on histologic characteristics [27]. In 
addition, molecular genetic parameters are used to more precisely define these tumor 
categories by assessing the presence or absence of mutations in the isocitrate 
dehydrogenase (IDH) genes IDH1 and IDH2 [27]. Furthermore, the absence of a combined 
loss (codeletion) of chromosomal arms 1p and 19q distinguishes IDH-mutant diffuse 
astrocytic gliomas from IDH-mutant and 1p/19q-codeleted oligodendroglial tumors [27, 34]. 
IDH mutation and 1p/19q codeletion status are, therefore, highly relevant diagnostic markers 
that are also closely linked to outcome of patients with diffuse gliomas [5, 46]. Consequently, 
an integrated histomolecular classification of diffuse gliomas must be used in current 
attempts at identifying new biomarkers that may prognostically stratify diffuse glioma patients 
and guide tumor grading. The identification of novel molecular alterations associated with 
patient outcome and the characterization of the pathomechanisms involved are also required 
for the design of risk-stratified treatment strategies for the different glioma entities. 
Chromosomal aberrations implicated in the progression and clinical aggressiveness of 
diffuse astrocytic gliomas are deletions of the entire chromosomal arm 9p or parts thereof 
(e.g. [5, 46]). These deletions are thought to preferentially target the cyclin dependent kinase 
inhibitor 2A and 2B (CDKN2A/B) genes at 9p21.3 [1, 6, 39]. In addition to CDKN2A/B, 
however, the 9p deletions commonly encompass several other genes potentially playing 
important roles in driving glioma progression [36]. We have previously shown that the 
KIAA1797/FOCAD gene located in close proximity to CDKN2A/B in the same chromosomal 
subband is also frequently deleted, and that the encoded focadhesin (FOCAD) functions as a 
tumor suppressor in glioblastoma [4]. FOCAD re-expression in glioblastoma cells with 
homozygous FOCAD deletion inhibited cell migration and invasion as well as proliferation in 
vitro and in vivo [4]. FOCAD deletions have also been implicated in the pathogenesis of other 
tumor entities, e.g. breast cancer, where somatic and germline deletions of the FOCAD gene 
Brand et al.  FOCAD loss in astrocytic gliomas   4
were described in sporadic cases without mutation in the BRCA1 DNA repair associated 
(BRCA1) gene [24, 29]. In addition, heterozygous microdeletions or truncating mutations of 
the FOCAD gene have been detected in the germline of colorectal cancer and adenomatous 
polyposis patients [17, 43, 48], corroborating a role for FOCAD haploinsufficiency or 
inactivation in the predisposition for and growth of various cancer entities.  
This study aimed at gaining further insights into the relevance of diminished FOCAD copy 
number for the pathogenesis of diffuse astrocytic gliomas and the pathomechanisms 
involved. We explored the frequency and prognostic value of diminished FOCAD copy 
number in a prospective cohort of patients with astrocytic gliomas of WHO grades II to IV. 
Since little is known about the cellular localization and function of FOCAD, we determined 
FOCAD binding partners in a yeast two-hybrid screen, visualized the cellular site of their 
interaction, and performed functional and biochemical assays to characterize how FOCAD 
functions as a tumor suppressor. We report that tubulin-binding FOCAD localizes to 
centrosomes impacting microtubule assembly and cell cycle progression in the G2/M phase, 
and that FOCAD loss is a prognostic marker for overall survival (OS) in patients with IDH-
mutant astrocytic gliomas. 
 
 
Materials and methods 
Patients and tumors 
The German Glioma Network (GGN, www.gliomnetzwerk.de) is a prospective, non-
interventional cohort study involving eight clinical centers at German university hospitals, 
which was supported by the German Cancer Aid from 2004 to 2012. All patients gave written 
informed consent for participation in the GGN and its translational research projects. All 
tumors were subjected to central pathology review (T.P.) and initially classified according to 
the WHO classification of tumors of the central nervous system of 2007 [26]. For this study, 
all tumors were reclassified according to the revised 4th edition of the WHO classification 
2016 [27] based on IDH1 and IDH2 (IDH) mutation status previously determined by direct 
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sequencing of tumor DNA and 1p/19q codeletion status [33, 46]. Data on 1p/19q codeletion 
as well as FOCAD and CDKN2A/B copy number were retrieved from previously reported 
array-based comparative genomic hybridization (CGH) results using the diagnostic cut-offs 
<-0.3 >-1 to score loss and ≤-1 to score homozygous deletion; O6-methylguanine-DNA-
methyltransferase (MGMT) promoter methylation status had been determined by 
methylation-specific PCR [33, 46]. In the present study, only gliomas without 1p/19q-
codeletion were included, thus restricting the prognostic association studies to patients with 
IDH-wildtype or IDH-mutant diffuse astrocytic gliomas. The clinical and pathologic 
characteristics of the study cohort are summarized in Table 1. The median follow-up was 8.5 
years (range: 0.6-17.7 years), with 85 deaths (63.9%) and 48 patients (36.1%) alive at last 
follow-up. 
 
Cells, transfection, and treatments 
HeLa S3 cells, HEK293T cells, human glioblastoma cell lines LN-18 (FOCAD-/-) and U-87MG 
(FOCAD-/-) with FOCAD homozygous deletions, LN-229 (FOCAD+/+) with balanced FOCAD 
and CDKN2A/B status according to high-resolution array-based CGH analysis [4] were 
cultured as described in Supplementary material online resource. Human astrocytes and 
culture medium were purchased from ScienCell (ScienCell Research Laboratories, Carlsbad, 
CA, USA). All cells were transfected using Lipofectamine 3000 (Thermo Fisher Scientific, 
Waltham, MA, USA). For cell synchronization at G1/S and M phase, double thymidine block 
(Sigma-Aldrich, St. Louis, MO, USA; 2 mM, 16 h each) or nocodazole (Sigma-Aldrich; 100 
ng/ml, 16 h) were applied. To assess protein stability, cells were treated with biosynthesis 
inhibitor cycloheximide (Sigma-Aldrich; 20 µg/ml), 26S proteasome inhibitors bortezomib 
(Sigma-Aldrich; 100 nM) or MG132 (Sigma-Aldrich; 10 µM).  
 
Plasmids 
The primers used to generate constructs are given in Supplementary material online 
resource. To generate the FOCAD yeast two-hybrid bait construct, the full-length open 
Brand et al.  FOCAD loss in astrocytic gliomas   6
reading frame (ORF) of FOCAD was amplified from cDNA derived from human astrocytes 
and cloned into the multiple cloning site of the bait vector pEG202 (MoBiTec, Göttingen, 
Germany), resulting in pEG202-FOCAD. To generate a construct expressing N-terminal 
GFP-tagged FOCAD, the FOCAD ORF was amplified from pEG202-FOCAD and subcloned 
into the pEGFP-C1 expression vector (Takara Bio) (=GFP-FOCAD). To generate a 
lentivector construct expressing C-terminal GFP-tagged FOCAD, the FOCAD-GFP cDNA 
was cloned 3' of a cytomegalovirus (CMV) promoter resulting in rrl-cPPT-CMV-FOCAD-GFP-
WPRE (=FOCAD-GFP). The lentivector plasmid was used for transient transfection. The 
pcDNA3.1 expression vector coding for untagged FOCAD was described previously [4]. The 
ORFs of TUBA1A, TUBB3, TUBB6, TUBG1, and SLAIN2 were amplified from Human 
Multiple Tissue cDNA Panel I (#636747, LOT1212243A; Takara Bio, Kusatsu, Japan) and 
subcloned into the pcDNA3.1-Myc (Thermo Fisher Scientific) or the pTagRFP (RFP) 
expression vector (Evrogen, Moscow, Russia). All constructs were verified by restriction 
enzyme digest and direct sequencing. The human full-length HSP90AB1 cDNA in a 
pcDNA3.1/GS expression vector was purchased from Thermo Fisher Scientific/Invitrogen.  
 
FOCAD bait yeast two-hybrid screen with a human brain cDNA prey library 
A yeast two-hybrid screen was performed according to the manufacturer’s protocol 
(MoBiTec). In brief, the pEG202-FOCAD bait vector coding for the DNA-binding domain of 
LexA fused to FOCAD was used together with prey vectors pJG4-5 comprising a human fetal 
brain cDNA library (Origene Technologies Inc, Rockville, MD, USA) under the control of the 
inducible GAL1 promoter and as translation fusions with the B42 acidic activator. The 
plasmids were transformed into the S. cerevisiae strain EGY48 (MATα, trp1, his3, ura3, 
leu2::6 LexAop-LEU2; MoBiTec). Positive yeast clones were identified by growth on synthetic 
defined (SD) medium supplemented with galactose (gal) and raffinose (raf) and lacking 
histidine, leucine, and tryptophan (SD(gal/raf)ΔHLT; all purchased from MoBiTec). False-
positive clones, which grew on SD medium supplemented with glucose (SD(glu)ΔHLT), were 
not characterized further. The remaining prey-inserts were analyzed by direct DNA 
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sequencing of yeast colony-PCR products amplified using the primer pair 5'-ATA TCG AGG 
AGT GCA ATG CC-3’ (forward) and 5’-GCC GAC AAC CTT GAT TG-3’ (reverse). 
Reconstitution of bait and prey interaction was verified by retransformation of yeast cells 
following the lithium acetate method described in the yeast protocol handbook (Takara Bio). 
Comparable growth of yeast co-transformants was verified on SD(gal/raf)ΔHT medium (with 
leucine) required for plasmid selection. 
 
Pull-down assays 
Binding of FOCAD to HSP90AB1 was verified using 6xHis-tag-mediated pull down as 
detailed in Supplementary material online resource. Binding of FOCAD to tubulin isoforms 
was assayed using Myc-tag-mediated pull down. HEK293T cells were transiently co-
transfected with constructs expressing N-terminal Myc-tagged TUBA1A, TUBB3, TUBB6 or 
TUBG1 and untagged FOCAD. At 24 h post transfection, cells were washed with ice-cold 
phosphate-buffered saline (PBS) and lysed for 30 min on ice in 1 ml of immunoprecipitation 
(IP) lysis buffer (20 mM Tris-HCl, pH 8.0), 50 mM sodium fluoride, 1 mM sodium 
orthovanadate, 1% Triton X-100, supplemented with protease and phosphatase inhibitors 
(Roche Diagnostics)). Cell lysates were incubated with 1 µg of anti-Myc antibody (sc-40; 
Santa Cruz Biotechnology, Dallas, TX, USA) by tumbling over night at 4°C. Protein G 
Sepharose beads (GE Healthcare, Little Chalfont, UK) were equilibrated in IP lysis buffer, 
blocked with 0.1% bovine serum albumin (BSA; Thermo Fisher Scientific) and incubated with 
the lysates for 4 h at 4°C. After five washing steps with IP lysis buffer, bound protein was 
eluted from the beads using Laemmli buffer (62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 2% 
SDS, 5% 2-mercaptoethanol, 1 mM EDTA, 0.01% bromophenol blue), and detected by 
Western blot analysis. 
 
Western blot analysis 
After sodium dodecylsulfate-polyacrylamide gel electrophoresis and semidry electroblotting, 
polyvinylidene difluoride or nitrocellulose membranes (GE Healthcare) were blocked with 5% 
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fat-free milk powder dissolved in PBS with 0.05% Tween 20 (PBST). Primary antibodies 
given in Supplementary material online resource were diluted in 5% (w/v) BSA in PBST and 
used for immunodetection. After incubation over night at 4°C, membranes were exposed to 
the appropriate horseradish peroxidase-conjugated secondary antibody (Santa Cruz 
Biotechnology; dilution 1:3,000) in 5% fat-free milk powder dissolved in PBST for 90 min at 
room temperature, and developed using the Pierce SuperSignal West Femto or Dura 
Substrate detection kit (Thermo Fisher Scientific). Signals were acquired using the Fusion 
FX7 gel documentation system (Vilber, Collégien, France).  
 
Generation of cell lines with stable GFP-tagged FOCAD expression or FOCAD 
knockdown 
To generate stable expression of GFP-tagged FOCAD, LN-18 and U-87MG (both FOCAD-/-) 
cells were transfected with pEGFP-C1 or pEGFP-C1-FOCAD (=GFP-FOCAD), and selected 
with 600 µg/ml geneticin (Thermo Fisher Scientific) for at least 14 days starting 48 h post 
transfection. GFP-positive cells were isolated at the Cell Sorting Core Facility of Hannover 
Medical School using a MoFlo™ XDP cell sorter (Beckman-Coulter, Brea, MA, USA). A 
stable FOCAD knockdown was generated in LN-229 (FOCAD+/+) cells as described in 
Supplementary material online resource.  
 
Immunofluorescence 
Cells were seeded on collagen-coated coverslips and transiently transfected, if necessary. 
For the enrichment of mitotic cells, LN-18 and HEK293T cells were analyzed 10 h after 
release from second thymidine block. All cells were fixed with 2% paraformaldehyde in 
PHEM buffer (60 mM PIPES, 27 mM HEPES, 10 mM EGTA, 4 mM MgSO4; adjusted to pH 
7.0) followed by treatment with methanol for 20 min at -20°C. Primary antibodies are given in 
Supplementary material online resource. Secondary antibodies were conjugated to Alexa 
Fluor 488 or 568 (Thermo Fisher Scientific). DNA was counterstained with 4',6-diamidino-2-
phenylindole (Sigma-Aldrich). Images were captured using a confocal (Leica DM IRB with a 
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TCS SP2 AOBS scan head, Leica Microsystems, Wetzler, Germany) or an epifluorescence 
microscope (Leica DM RXA2) equipped with a cooled charge-coupled device camera 
(SenSys, Photometrics, Tucson, AZ, USA). 
 
Centrosome enrichment 
Centrosomal fractions were prepared from asynchronous HEK293T and LN-229 cells that 
were preincubated with 60 ng/ml nocodazole and 1 µg/ml cytochalasin D (Sigma-Aldrich) for 
1 h at 37°C. Cell lysis was performed using 1 mM Tris-HCl (0.1% 2-mercaptoethanol, 0.5% 
Triton X-100; adjusted to pH 8.0) by gently rocking cell culture dishes for 10 min at room 
temperature. Cell lysates were loaded on a 20% Ficoll (F9378, Sigma-Aldrich) cushion and 
centrifuged at 20,000 x g for 30 min at 4°C. After centrifugation, several 500 µl fractions were 
collected from 5 ml above to 2 ml below the interface and examined by Western blot 
analysis.  
 
Cellular microtubule regrowth assay 
LN-18 cells stably expressing GFP-FOCAD or GFP were plated on glass coverslips, 
incubated with 10 μM nocodazole for 5 h under standard growth conditions to induce 
microtubule depolymerisation, and washed three times in medium to remove nocodazole. 
Microtubules were then allowed to re-grow for 5 min at 37°C before cells were fixed with ice-
cold methanol and stained with anti-TUBA (dilution 1:2,000) to visualize microtubules. Mean 
length of microtubules nucleated by centrosomes was determined graphically on z-
projections obtained by confocal laser scanning microscopy using ImageJ software 
(http://imagej.nih.gov/ij/). Per cell line, a total of 100 cells from two independent experiments 
were evaluated. 
 
Live-cell imaging to track RFP-SLAIN2 trajectories 
LN-18 cells stably expressing GFP or GFP-FOCAD were seeded on collagen-coated glass 
bottom dishes (Ibidi, Martinsried, Germany) and transfected with RFP-SLAIN2 vector. Live-
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cell imaging was done using a Nikon microscope (Nikon, Tokyo, Japan) equipped with an 
Andor/Yokogava Spinning disk X1 and an Andor EMCCD camera (Oxford Instruments, 
Abingdon, UK). A stage-top incubator was used to keep cells at 37°C, and cells were imaged 
in CO2-independent medium (Thermo Fisher Scientific). RFP fluorescence signals in the 
cytoplasm were acquired with 0.2 s exposure time without delay between frames for about 
60 s. To track RFP-SLAIN2 comets, image series were analyzed using the Mosaic 
ParticleTracker 2D and 3D plugin, v1.6, http://mosaic.mpi-cbg.de/ParticleTracker/ [37] of the 
ImageJ software. For each of the two cell types, i.e. GFP and GFP-FOCAD expressing LN-
18 cells, average RFP-SLAIN2 comet velocity (micrometers per minute) was calculated 
based on mean values from all RFP-SLAIN2 trajectories detectable for at least 5 frames (1 s) 
per cell (n>125) in a total of 30 cells from three independent experiments.  
 
Flow cytometry of propidium iodide-stained cells 
LN-18 and LN-229 cells were fixed in ice-cold 70% ethanol at 4°C for at least 16 h. After 
resuspending the cell pellets in PBS, 40 µg/ml propidium iodide and 100 µg/ml RNase A 
(both from Sigma-Aldrich) were added for 30 min at 37°C for DNA staining. Fluorescence 
intensities were measured using a FACSCanto II flow cytometer (Becton Dickinson, Franklin 
Lakes, NJ, USA). Data processing was done using the Flowing Software 2 (http://www. 
uskonaskel.fi/flowingsoftware/).  
 
Cell viability assay in response to PLK1 inhibitor BI 6727 (volasertib) 
LN-229 cells (8.0 x 103) were seeded in 96-well plates and cultured over night using normal 
growth medium. BI 6727 (#18193; Cayman Chemicals, Ann Arbor, MI, USA) was added to a 
final concentration of 100 nM. After 48 h, the number of viable cells was determined by using 
the CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS; Promega, Madison, 
WI, USA) and recording absorbance at 490 nm with a FLUOstar Omega microplate reader 
(BMG Labtech, Ortenberg, Germany). 
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Statistical analysis 
OS was calculated from the day of first surgery until death or end of follow-up. Logrank test 
was used to analyze survival data. Cox regression models were built to assess the 
association of diminished FOCAD copy number with OS. Fisher’s exact test was used to test 
for association of clinical variables. All statistical analyses related to tumors and OS were 
performed using the IBM SPSS Statistics (version 25) software. Functional, cellular, and 
biochemical assays were statistically evaluated using the two-tailed Student’s t-test; values 




The frequency of FOCAD loss increases with WHO grade in diffuse astrocytic gliomas 
We have previously shown KIAA1797/FOCAD to be frequently deleted in glioma cell lines 
and a small series of glioblastomas [4]. Using array-based CGH analysis, we determined 
FOCAD copy number in 133 diffuse astrocytic tumors of WHO grades II to IV, including 36 
diffuse astrocytomas, IDH-mutant, WHO grade II, 27 anaplastic astrocytomas, IDH-mutant, 
WHO grade III, 8 glioblastomas, IDH-mutant, WHO grade IV, and 62 glioblastomas, IDH-
wildtype, WHO grade IV. Among the IDH-mutant tumors, diffuse astrocytomas (WHO grade 
II) rarely demonstrated FOCAD loss (in 5.6% of cases), while this alteration was detected in 
22.2% of anaplastic astrocytomas (WHO grade III) and 37.5% of glioblastomas (WHO grade 
IV). Thus, the rate of FOCAD loss increased with WHO grade in IDH-mutant diffuse 
astrocytic gliomas (p=0.025), whereas FOCAD homozygous deletion was not observed. Of 
all analyzed tumor entities, a diminished FOCAD copy number was most common in IDH-
wildtype glioblastomas (51.6%) including FOCAD loss in 35.5% and FOCAD homozygous 
deletion in 16.1% of cases (Table 2). 
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FOCAD loss is associated with inferior OS in patients with IDH-mutant astrocytic 
gliomas 
Next, we explored the potential prognostic role of diminished FOCAD copy number in our 
cohort of 133 patients. FOCAD loss was associated with increased risk of death with a HR of 
2.6 (95% CI 1.1-6.2) in the group of patients with IDH-mutant tumors (Fig. 1a). In contrast, no 
association of diminished, i.e. loss or homozygous deletion, versus balanced FOCAD copy 
number with OS was seen in the group of patients with IDH-wildtype glioblastomas (HR=1.1 
95% CI 0.6-1.8) (Fig. 1b). 
In multivariate analysis of a cohort of 125 patients with available data for all items 
considering patient age at diagnosis, IDH mutation status, MGMT promoter methylation 
status, and absence or presence of CDKN2A/B homozygous deletion, FOCAD loss retained 
significance as a prognostic marker (Table 3). An interaction term for FOCAD and IDH status 
was included and tested (p=0.025). This interaction term emphasized the significant 
difference in OS for diminished, i.e. loss or homozygous deletion, versus balanced FOCAD 
copy number in patients with IDH-mutant astrocytic gliomas (HR=2.9, 95% CI 1.2-7.1, 
p=0.023) versus patients with IDH-wildtype glioblastomas (HR=0.8, 95% CI 0.4-1.6, p=0.480) 
after adjustment for age, MGMT promoter methylation status, and CDKN2A/B homozygous 
deletion status.  
 
FOCAD and a C-terminal fragment of tubulin beta-6 (TUBB6) interact in a yeast two-
hybrid screen 
To explore the molecular basis of the prognostic effect associated with FOCAD loss, we 
screened for FOCAD-interacting proteins using a yeast two-hybrid system. The S. cerevisiae 
strain EGY48 was co-transformed with FOCAD as bait in a LexA fusion pEG202 vector and a 
human fetal brain cDNA library in a B42-expressing pJG4-5 prey vector. Within the screen, 
we analyzed specific growth of about 3.5 x 106 distinct co-transformants. Prey vectors from 
the 20 colonies specifically growing on glucose-free galactose/raffinose (SD(gal/raf)ΔHLT) 
but not on glucose-containing (SD(glu)ΔHLT) plates (Fig. 2a), which are considered to be 
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true-positive clones, were analyzed by direct DNA sequencing. Thereby, in-frame fragments 
from three genes were identified, one of which was not followed up because it encodes the 
C-terminus of a nuclear protein while FOCAD is located in the cytoplasm. The other two 
sequence fragments encode the C-terminus of heat shock protein 90 alpha family class B 
member 1 (HSP90AB1; amino acids 641-724) and TUBB6 (amino acids 354-446). Binding of 
FOCAD to full-length HSP90AB1 was verified by pull-down assay (Suppl. Fig. 1 online 
resource), whereas the functional relevance of this interaction was not analyzed further. The 
interaction between FOCAD and the TUBB6-fragment was confirmed by retransforming a 
fresh yeast EGY48 clone with several combinations of bait vectors, i.e. pEG202-FOCAD, 
pEG202 empty (negative control), or pEG202-p53 (positive control), and prey vectors, i.e. 
pJG4-5-TUBB6 (amino acids 354-446), pJG4-5 empty (negative control), or pJG4-5-LTA 
(positive control). Thereby, yeast growth on SD(gal/raf)ΔHLT selective medium was only 
observed for FOCAD-TUBB6 (amino acids 354-446) and p53-LTA co-transformants (Fig. 
2b). Comparable growth of yeast co-transformants was verified on SD(gal/raf)ΔHT (with 
leucine) medium (Fig. 2b).  
 
FOCAD binds to several members of tubulin subfamilies, including tubulin gamma-1 
(TUBG1) 
To verify FOCAD interaction with full-length TUBB6 and to investigate potential binding to 
other tubulin isoforms of the alpha-, beta-, and gamma-tubulin subfamilies, we performed 
pull-down assays on lysates of transiently transfected HEK293T cells. Thereby, co-elution of 
untagged FOCAD from protein-G-sepharose beads was shown after immunoprecipitation 
(IP) of Myc-TUBB6 using an anti-Myc antibody (Fig. 2c), and after IP of the isoform most 
homologous to TUBB6, i.e. tubulin beta-3 (TUBB3), which was also Myc-tagged (Fig. 2d). 
Interestingly, FOCAD co-precipitation was also detected after IP of Myc-TUBG1 (Fig. 2e), 
whereas binding to Myc-tagged tubulin alpha-1A (TUBA1A) was not observed (Fig. 2f).  
 
  
Brand et al.  FOCAD loss in astrocytic gliomas   14
FOCAD is enriched at the centrosome in proximity to centrioles 
To visualize the cellular site of FOCAD interaction with TUBB6, TUBB3 and tubulin gamma 
(TUBG), immunofluorescence experiments were performed. By transiently expressing GFP-
tagged FOCAD in U-87MG cells carrying a homozygous FOCAD deletion (FOCAD-/-; [4]), co-
localization of FOCAD-GFP with overexpressed Myc-TUBB6 and endogenous TUBB3 and 
TUBG was detected at the centrosome (Fig. 3a, arrows).  
To verify the centrosomal and estimate the subcentrosomal localization of FOCAD, co-
localization studies with the endogenous centriole-associated proteins centrin (CETN) and 
SAS-6 centriolar assembly protein (SASS6) in addition to TUBG, primarily localized at the 
pericentriolar matrix (PCM) surrounding the centrioles, were performed in interphase and 
mitotic LN-18 cells stably expressing GFP-FOCAD. Using epifluorescence and confocal 
microscopy, the TUBG signal showing a PCM-like pattern only partially co-localized with the 
centriolar-shaped GFP-FOCAD signal (Fig. 3b, Suppl. Fig. 2 online resource). Two distinct 
centrioles were visualized by staining with anti-CETN, and GFP-FOCAD showed a similar 
staining pattern. Compared to staining of SASS6, which is functionally involved in 
procentriole formation, GFP-FOCAD signals were more diffuse and also found at other 
centrosomal loci. Taken together, FOCAD was found in close proximity to centriole pairs in 
interphase and mitotic cells (Fig. 3b).  
To exclude artefacts caused by ectopic expression or by interaction with the GFP-tag, we 
carried out centrosome enrichment by centrifugation using normal HEK293T cells and LN-
229 cells without FOCAD deletion [4]. Several fractions of total cell lysates around the phase 
interface were examined by Western blot analysis. In both cell lines, greatest abundance of 
endogenous FOCAD was found in those fractions that contained highest levels of TUBG and 
CETN, which is direct evidence that FOCAD is a centrosomal component (Fig. 3c). 
Moreover, immunostaining with anti-FOCAD and anti-TUBG antibodies confirmed partial co-
localization at the centrosome in human astrocytes expressing endogenous FOCAD [4], but 
not in LN-18 cells carrying a homozygous FOCAD deletion (FOCAD-/-; [4]) (Suppl. Fig. 3 
online resource). 
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FOCAD is recruited to microtubules via SLAIN motif family member 2 (SLAIN2) and 
has functional relevance on microtubule dynamics 
This study establishes FOCAD as a tubulin-binding protein localizing to centrosomes. 
Recently, FOCAD was shown to interact with SLAIN2 [16], a key component of the 
microtubule plus-end tracking protein network [41]. Therefore, we went on to visualize 
FOCAD and SLAIN2 interactions on a cellular level. After transient overexpression of 
FOCAD-GFP and RFP-SLAIN2 in HEK293T cells and human astrocytes, both proteins co-
localized at interphase and metaphase centrosomes (Fig. 4a, b), at the prometaphase 
spindle (Fig. 4b), and at microtubules, where FOCAD-GFP was translocated in the presence 
of RFP-SLAIN2 (Fig. 4a, b, Suppl. Fig. 4 online resource).  
To investigate the relevance of FOCAD for microtubule growth and assembly, we 
analyzed (i) cellular microtubule regrowth after release from the microtubule-depolymerizing 
agent nocodazole and (ii) microtubule growth velocity / assembly rate measured by RFP-
SLAIN2 movement at the growing microtubule plus-ends by live-cell imaging, in LN-18 cells 
(FOCAD-/-) stably transfected with GFP-FOCAD or GFP. Mean length of microtubules 
nucleated by centrosomes 5 min after nocodazole wash out (Fig. 4c), and mean RFP-
SLAIN2 comet velocity (Fig. 4d, e) were significantly reduced in LN-18 cells expressing GFP-
FOCAD versus GFP. Both experiments demonstrated a functional relevance of FOCAD for 
microtubule dynamics, indicating significantly slower microtubule growth rates in the 
presence of FOCAD presumably due to a reduction of SLAIN2 activity at microtubule plus-
ends.  
 
FOCAD levels peak in G2/M phase, and stable FOCAD knockdown accelerates 
progression through G2/M 
We have previously shown that FOCAD decreases glioma cell growth in vitro and in vivo [4]. 
Here, we explored whether FOCAD impacts cell cycle regulation using a knockdown model 
of FOCAD expressing LN-229 cells. To monitor FOCAD expression during the cell cycle, 
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control LN-229 cells stably transduced with a non-targeted shRNA (control shRNA) were 
synchronized in G1/S or M phase with a double thymidine or nocodazole block procedure. At 
specific time points after release from these blockades, endogenous FOCAD levels in cell 
lysates were analyzed by immunoblotting using an anti-FOCAD antibody (Fig. 5a). Histone 
H3 phosphorylation associated with highly condensed chromatin served as a mitotic marker. 
FOCAD expression peaked 8-10 h after release from blockade in G1/S phase and 24 h after 
release from M phase block. Both time points represent G2/M phase as indicated by strongly 
positive phosphorylation of histone H3 starting around 10 h after release from G1/S and 24 h 
after release from M phase blockade (Fig. 5a). Similar results were obtained when studying 
synchronized LN-18 and HeLa S3 cells overexpressing FOCAD-GFP (Suppl. Fig. 5 online 
resource). Treatment with the 26S proteasome complex inhibitors bortezomib and MG132 
suggested regulation of FOCAD protein levels by the ubiquitin proteasome pathway, 
including the 26S proteasome (Suppl. Fig. 6 online resource), which is involved in cell cycle 
progression. 
Stable FOCAD knockdown (FOCAD shRNA) accelerated progression through the G2/M 
phase of the cell cycle compared to control shRNA knockdown in LN-229 cells (Fig. 5b-d). 
This was shown using flow cytometry by measuring DNA content in propidium iodide-stained 
LN-229 FOCAD knockdown versus control cells. Differences in time-dependent cell cycle 
progression were most pronounced at 8-10 h after release from G1/S block, i.e. during G2/M 
phase, when FOCAD expression levels were highest in control cells (Fig. 5a-c). The detected 
knockdown effect was partially reversed after stable re-expression of FOCAD in knockdown 
cells (FOCAD shRNA + rescue; Fig. 5b, c). Similarly, accelerated G2/M progression and 
earlier entry into mitosis in FOCAD knockdown versus control cells reversed by FOCAD re-
expression were shown by Western blot analysis of G2/M regulator cyclin B1 expression and 
mitotic marker histone H3 phosphorylation, in the LN-229 knockdown model (Fig. 5d).  
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FOCAD influences polo like kinase 1 (PLK1) T210 phosphorylation, and stable FOCAD 
knockdown increases sensitivity to the PLK1 inhibitor volasertib 
Since PLK1 is a key signaling molecule in cell cycle progression with an important role in 
mitotic entry regulation [28, 38], activating PLK1 T210 phosphorylation was analyzed in the 
LN-229 FOCAD knockdown model (Fig. 5e, f). Eight hours after release from G1/S block 
when FOCAD expression was high and the effect of FOCAD knockdown on cell cycle 
progression and mitotic entry commenced, PLK1 T210 phosphorylation was significantly 
enhanced in FOCAD knockdown versus control cells (Fig. 5e, f). Therefore, in the LN-229 
FOCAD knockdown model we explored whether a PLK1 inhibitor would have an enhanced 
effect in cells with reduced FOCAD expression. Incubation with the PLK1 inhibitor BI 6727 
(volasertib) was found to significantly decrease viability of FOCAD knockdown compared to 
control cells (Fig. 5g). These data suggest that patients with astrocytic gliomas carrying a 




Established prognostic factors for OS of patients with diffuse astrocytic gliomas include age 
at diagnosis as well as IDH mutation and MGMT promoter methylation status of the tumor 
DNA [47]. In the present study, diminished copy number of the FOCAD tumor suppressor 
gene was found to be most common in tumors of the highest malignancy grade (WHO grade 
IV), in particular in the clinically most aggressive IDH-wildtype glioblastomas, the only 
examined tumor entity harboring FOCAD homozygous deletion in a subset of cases (16.1%). 
Moreover, we found that FOCAD loss was associated with inferior outcome in patients with 
IDH-mutant diffuse astrocytic gliomas of WHO grades II to IV irrespective of age at diagnosis 
as well as MGMT promoter methylation and CDKN2A/B homozygous deletion status. In line 
with our findings, loss of 9p21.3, where FOCAD is located in close proximity to the 
CDKN2A/B tumor suppressor gene locus, has previously been implicated in the 
pathogenesis and the prognosis of various types of tumors, including gliomas. In a recent 
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PanCancer and PanSoftware analysis spanning 9,423 tumor exomes across 33 cancer types 
to catalog driver genes and mutations, the CDKN2A deletion at 9p21.3 was the most 
common putatively actionable alteration in 13% of exomes from all tumors and over 40% of 
glioblastoma exomes [2]. In IDH-mutant astrocytic gliomas, homozygous CDKN2A/B 
deletions arise during tumor progression and have been associated with shorter OS [1, 22, 
39]. However, similar to deletions on 1p and 19q that are chromosomal hallmarks of 
oligodendroglioma, the 9p deletions harboring the CDKN2A/B locus in astrocytic gliomas are 
frequently large, encompassing a chromosomal subband to an entire chromosomal arm [20, 
33, 35, 46]. Therefore, it is likely that the broad 9p deletions target more than one driver gene 
locus. Accordingly, in an effort to identify potential drivers in large 9p deletions in lower grade 
gliomas, Roy et al. reported that while CDKN2A homozygous deletion was associated with 
poor OS in The Cancer Genome Atlas (TCGA) and validation cohorts, heterozygous 
CDKN2A loss and absent CDKN2A mRNA expression without biallelic CDKN2A deletion 
were not [36]. Furthermore, their results support the notion that the inactivation of several 
genes, such as PTPRD and PLAA encoding protein tyrosine phosphatase receptor type D 
and phospholipase A2 activating protein as well as MTAP and KLHL9 coding for 
methylthioadenosine phosphorylase and kelch like family member 9, likely causes 
cumulative haploinsufficiency that contributes to tumor aggressiveness in lower grade 
gliomas [36]. These authors also describe a significantly reduced FOCAD mRNA expression 
in TCGA lower grade gliomas, in line with evidence from this study that FOCAD is a gene on 
9p21.3 the loss of which plays a role in the clinical outcome of patients with IDH-mutant 
astrocytic gliomas.  
To support our data suggesting that diminished FOCAD copy number is associated with 
astrocytic glioma aggressiveness, we sought to gain further insights into how FOCAD 
functions as a tumor suppressor. The finding from a yeast two-hybrid screen that FOCAD 
interacted with TUBB6 led us to localize FOCAD to the interphase and mitotic centrosome. 
Several other tumor suppressors, including the APC regulator of WNT signaling pathway 
[12], BRCA1 [18], checkpoint kinase 1 [23], and tumor protein p53 [8] are known to be 
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permanently or temporarily associated to the centrosome. Numerical and structural 
centrosome aberrations are hallmarks of almost all solid tumors including tumors of the brain 
and have been implicated in their etiology [32, 45] (reviewed in [30]). As the centrosome is 
the main microtubule-organizing center within mammalian cells involved in regulating a 
variety of important cellular processes, including cell motility, cell cycle progression, and 
chromosome segregation (reviewed in [44]), it is quite conceivable that deficiency of a 
centrosomal protein may promote invasive behavior.  
Besides localizing FOCAD to centrosomes, this study provides evidence that FOCAD is 
recruited to interphase microtubules and mitotic spindles when co-expressed with FOCAD-
interacting SLAIN2 [16] and affects microtubule dynamics. These cellular organelles are 
linked in that centrosomes stabilize the minus ends of microtubules that extend their dynamic 
plus ends toward the cell periphery. Microtubules play a pivotal role in cell migration, e.g. by 
regulating lamellipodial protrusion formation and focal adhesion dynamics (reviewed in [14]), 
and their alterations have been linked to cancer progression (reviewed in [9]). Recently, 
Osswald and colleagues showed that astrocytic gliomas form ultra-long membrane 
protrusions, so called tumor microtubes, used as routes for brain invasion and to 
interconnect over long distances, which contain microtubules [31]. Here, we demonstrated 
reduced microtubule growth rates and diminished comet velocity of microtubule plus-end 
binding protein SLAIN2 [41], which promotes cell elongation [3], in the presence of FOCAD. 
Therefore, in astrocytic gliomas with diminished FOCAD copy number showing increased 
microtubule assembly rates, tumor microtube formation may be enhanced. This molecular 
mechanism may underlie their proliferative and invasive phenotype that we previously 
detected in vitro and in vivo using an orthotopic xenograft mouse model [4]. As we have 
previously shown that FOCAD localizes to focal adhesions [4], i.e. close contacts with the 
extracellular matrix the dynamics of which are regulated by microtubules (reviewed in [40]), 
invasive behavior of glioma cells with diminished FOCAD copy number may additionally 
result from dysregulation of focal adhesions. Moreover, because FOCAD can be recruited to 
microtubules (this study) and focal adhesions [4], it is tempting to speculate that FOCAD may 
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be relevant for the control of microtubule-mediated focal adhesion turnover, e.g. by acting as 
an adaptor protein connecting microtubules and focal adhesions. Such a role in coordinating 
microtubules at focal adhesions to direct cell migration has recently been described for tumor 
suppressor APC [19]. Linking FOCAD loss to increased microtubule assembly with potential 
implications for focal adhesions and the formation of tumor microtubes, provides further 
evidence for a role of FOCAD loss in enhanced cell motility and aggressive glioma behavior. 
Here, FOCAD protein levels were shown to peak in G2/M phase resulting in accelerated 
G2/M progression upon FOCAD knockdown, and indicating functional relevance of FOCAD 
during G2/M phase. Consequently, FOCAD inhibits different phases of the cell cycle 
compared to G1/S phase inhibitors p15 and p16 encoded by CDKN2A/B (reviewed in [25]). 
Therefore, in astrocytic gliomas with broad 9p deletions encompassing FOCAD as well as 
CDKN2A/B the cell cycle is accelerated in G2/M as well as G1/S phase, thereby additively 
promoting growth and diminishing genomic integrity. Furthermore, our data suggest that 
FOCAD may interfere in cell cycle regulation via the mitotic protein kinase PLK1. 
Hyperactivation of PLK1 found in many human tumors including gliomas [11] is broadly 
associated with progression and poor prognosis, e.g. of glioma patients [7]). Not only did 
cells with reduced FOCAD expression exhibit an increased PLK1 activity, they also showed 
an enhanced sensitivity to PLK1 inhibitor BI 6727 (volasertib) compared to control cells. 
Volasertib has clinical efficacy in a range of malignancies and is currently in phase III 
development as a potential treatment for patients with acute myeloid leukemia 
(ClinicalTrials.gov ID: NCT01721876) (reviewed in [15]). However, there is also preclinical 
evidence for a role of PLK1 inhibition in the treatment of gliomas. In an in vitro screen of 160 
small molecule kinase inhibitors, a PLK1 inhibitor selectively disrupted proliferation of 
glioblastoma-derived but not normal neural stem cells [10]. In xenograft mouse models, 
PLK1 inhibition enhanced temozolomide efficacy in IDH1-mutant gliomas [21], and combined 
volasertib and radiation significantly inhibited growth of glioma stem cells and prolonged 
median survival compared with radiation treatment alone [13]. According to our data, the use 
of PLK1 inhibitors may be especially beneficial for patients suffering from astrocytic gliomas 
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with diminished FOCAD copy number, including pleomorphic xanthoastrocytomas that 
frequently harbor large 9p losses [42]. 
In conclusion, we demonstrated FOCAD loss as a prognostic factor for OS of patients with 
IDH-mutant astrocytic gliomas. By showing that FOCAD (i) is a tubulin binding protein 
localizing to centrosomes and recruited to microtubules via interaction with SLAIN2, (ii) 
diminishes microtubule assembly, and (iii) delays G2/M progression in glioma cells possibly 
by regulating PLK1 activation, we elucidated FOCAD-dependent molecular mechanisms, 
which when deregulated due to diminished FOCAD copy number may increase biological 
aggressiveness of diffuse astrocytic gliomas. Prospectively, the identified cellular alterations 
caused by FOCAD loss may guide the development of therapeutic approaches specifically 
tailored for astrocytic gliomas carrying a FOCAD deletion, e.g. PLK1 inhibition. 
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Table 1. Patient characteristics 
 All patients (n=133) 
Age at diagnosis (years)  
Median (range) 44 (21-80) 
Gender  
Male 87 (65.4%) 
Female 46 (34.6%) 
Histology  
Diffuse astrocytoma,  
IDH-mutant, WHO grade II 
36 (27.1%) 
Anaplastic astrocytoma,  
IDH-mutant, WHO grade III 
27 (20.3%) 
Glioblastoma, IDH-mutant, WHO grade IV 8 (6.0%) 
Glioblastoma, IDH-wildtype, WHO grade 
IV 
62 (46.6%) 
Initial surgery  
Gross total resection 52 (44.1%) 
Subtotal resection (50-99%) 40 (33.9%) 
Partial resection (<50%) 22 (18.6%) 
Biopsy 4 (3.4%) 
Not available 15 
First-line post-operative therapy  
No therapy 39 (29.3%) 
Radiotherapy alone 15 (11.3%) 
Chemotherapy alone 4 (3.0%) 
Radiotherapy plus chemotherapy 75 (56.4%) 
Karnofsky performance score  
90-100 69 (56.6%) 
70-80 47 (38.5%) 
<70 6 (4.9%) 
Not available 11 
Death  
No 48 (36.1%) 
Yes 85 (63.9%) 
MGMT promoter methylation status  
Methylated 89 (67.4%) 
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Unmethylated 43 (32.6%) 
Not available 1 
IDH status  
Mutated 71 (53.4%) 
Wildtype 62 (46.6%) 
FOCAD status  
Loss  33 (24.8%) 
Homozygous deletion 10 (7.5%) 
Balanced 90 (67.7%) 
CDKN2A/B status  
Homozygous deletion 30 (23.8%) 
No homozygous deletion 96 (76.2%) 
Not available 7 
Loss (cut-offs <-0.3 >-1.0); homozygous deletion (cut-off ≤-1.0) 
 

















WHO grade IV 
n=70 
All tumors 
WHO grades II-IV 
n=133 
 IDH-mutant IDH-mutant IDH-mutant IDH-wildtype Total IDH-mutant IDH-wildtype Total 
FOCAD 
  Loss 
  Homo del 
  Balanced 
 




























  33 (24.8%) 
  10 (7.5%) 
  90 (67.7%) 
Total 36 (100%) 27 (100%) 8 (100%) 62 (100%) 70 (100%) 71 (100%) 62 (100%) 133 (100%) 
Loss (cut-offs <-0.3 >-1.0); homo del, homozygous deletion (cut-off ≤-1.0) 
 
 








Table 3. Multivariate analysis for OS of the patient cohort (n=125*), i.e. astrocytomas, 
IDH-mutant, WHO grade II (n=33), anaplastic astrocytomas, IDH-mutant, WHO grade III 
(n=24), glioblastomas, IDH-mutant, WHO grade IV (n=8), and glioblastomas, IDH-
wildtype, WHO grade IV (n=60)  
 HR 95% CI p-value 
FOCAD 















Test for interaction 
































*Eight patients were excluded from multivariate analysis because the MGMT promoter 
methylation status (n=1) or the CDKN2A/B homozygous deletion status (n=7) were not 
available 
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Figure legends 
Fig. 1 Associations of diminished FOCAD copy number with OS in a series of 133 patients 
with IDH-mutant diffuse astrocytomas, anaplastic astrocytomas, glioblastomas or IDH-
wildtype glioblastomas. Kaplan-Meier plots showing the association of FOCAD loss with 
inferior outcome in pooled IDH-mutant diffuse astrocytomas, anaplastic astrocytomas and 
glioblastomas (a), while FOCAD loss or homozygous deletion were not associated with OS in 
IDH-wildtype glioblastomas (b). FOCAD homozygous deletion was not detected in IDH-
mutant tumors. AII, diffuse astrocytoma, WHO grade II; AAIII, anaplastic astrocytoma, WHO 
grade III; GBM, glioblastoma, WHO grade IV; wt, wildtype; mut, mutant; homo del, 
homozygous deletion (cut-off ≤-1.0); loss (cut-offs <-0.3 >-1.0). 
 
Fig. 2 FOCAD is a tubulin-binding protein. a The coding sequence of FOCAD was used as 
bait and a human brain cDNA library as prey in a yeast two-hybrid screen. The FOCAD-bait 
protein showed positive interaction with a prey-protein subsequently found to contain a C-
terminal fragment of TUBB6 (amino acid sequence 354-446), as indicated by growth of the 
yeast strain co-expressing both vectors on synthetic defined (SD) medium containing 
galactose and raffinose (SD(gal/raf)ΔHLT). Specificity of bait and prey interaction was 
confirmed by growth inhibition of the yeast co-transformants on SD medium containing 
glucose (SD(glu)ΔHLT) because of glucose-induced suppression of the GAL1 promoter 
controlling expression of the prey vector. b The interaction of FOCAD and the TUBB6-
fragment was verified by a retransformation experiment with combinations of several bait and 
prey vectors. Only yeast co-transformants with FOCAD bait- and TUBB6 prey-vector grew on 
SD(gal/raf)ΔHLT selective medium, as shown for p53-bait and LTA-prey co-transformants 
used as positive control. Comparable growth of yeast co-transformants was verified on 
SD(gal/raf)ΔHT medium required for plasmid selection. c-f To test the ability of full-length 
TUBB6 and further tubulin subfamily members to bind FOCAD, HEK293T cells were 
transiently transfected with untagged FOCAD and/or one of several Myc-tagged tubulin 
isoforms. FOCAD was co-purified by immunoprecipitation (IP) using an anti-Myc antibody. 
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FOCAD was found to bind to full-length Myc-TUBB6 (c), to its most closely related isoform, 
i.e. TUBB3, which was also Myc-tagged (d), and to Myc-TUBG1 (e), but not to Myc-TUBA1A 
(f). Myc-tagged tubulins were detected using an anti-Myc antibody. †, fragment spanning 
amino acid residues 354-446; arrowhead, position of the specific tubulin bands; asterisk, 
heavy chain of the anti-Myc antibody used for IP. 
 
Fig. 3 FOCAD localizes to the centrosome in proximity to centrioles. a FOCAD-GFP co-
localized with overexpressed Myc-TUBB6, endogenous TUBB3 and TUBG at the 
centrosome (arrows) in transiently transfected U-87MG cells (FOCAD-/-). b 
Immunofluorescence co-staining with TUBG, CETN, and SASS6 revealed subcentrosomal 
localization of GFP-FOCAD close to the centriole pairs (inserts with higher magnification) in 
stably transfected interphase and mitotic LN-18 cells (FOCAD-/-). c After enriching 
centrosomes by centrifugation, endogenous FOCAD levels were measured in fractions of 
HEK293T and LN-229 cell lysates and total cell lysates (TCL). FOCAD levels peaked in the 
same fractions as the centrosomal marker proteins TUBG and CETN. Scale bar = 2.5 µm (a 
and b). 
 
Fig. 4 FOCAD is translocated to microtubules via plus-end tracking protein SLAIN2 and 
reduces microtubule regrowth and SLAIN2 comet velocity. a FOCAD-GFP was translocated 
to microtubules in interphase HEK293T cells co-overexpressing SLAIN2, while its localization 
was diffusely cytoplasmic and centrosomal in cells expressing FOCAD-GFP only. b In 
addition to co-localizing at centrosomes and microtubules in interphase, FOCAD-GFP and 
RFP-SLAIN2 co-localized at spindle poles and spindles from prometaphase to anaphase in 
HEK293T cells transiently overexpressing both proteins. c Microtubule (MT) regrowth was 
significantly reduced in LN-18 cells (FOCAD-/-) expressing GFP-FOCAD versus GFP. 
Microtubule regrowth was measured after release from 5 h treatment with 10 µM nocodazole 
in LN-18 cells (FOCAD-/-) stably expressing GFP-FOCAD or GFP that were fixed 5 min after 
nocodazole wash out and stained with anti-TUBA. Microtubule regrowth was quantified by 
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measuring microtubule length nucleated by centrosomes in 50 cells with stable GFP-FOCAD 
or GFP expression per experiment (mean ± SD of two independent experiments, 
representative images of each cell line are shown). d Average RFP-SLAIN2 comet velocity 
was significantly reduced in LN-18 cells (FOCAD-/-) expressing GFP-FOCAD versus GFP. 
LN-18 cells (FOCAD-/-) stably expressing GFP-FOCAD or GFP were transiently transfected 
with RFP-SLAIN2 and time-lapse confocal microscopy of RFP-SLAIN2 comets was 
performed for intervals of 60 seconds recording 5 frames per second. The trajectories of 
RFP-SLAIN2 comets were analyzed using the Mosaic Particletracker 2D and 3D plugin of 
the ImageJ software. Scatter dot plots show average RFP-SLAIN2 comet velocity (>125 
trajectories per cell, mean of 30 cells from three independent experiments per cell line). e 
Measurement of RFP-SLAIN2 comet velocity in LN-18 cells (FOCAD-/-) stably expressing 
GFP-FOCAD or GFP. Shown are representative overlays of three successive time-lapse 
images taken at 4 second intervals, whereby the first, second, and third images were 
pseudocolored in red, green, and blue, respectively. The boxed regions are shown at higher 
magnification on the right, and 2-3 representative trajectories of RFP-SLAIN2 comets in each 
image are marked. *, p < 0.05; **, p ≤ 0.01 (Student’s t test). Scale bar = 5 µm (a, b, c, and 
e). 
 
Fig. 5 FOCAD protein levels peak in G2/M phase of the cell cycle, and reduced FOCAD 
expression accelerates progression through G2/M, enhances PLK1 activating T210 
phosphorylation and decreases cell viability upon PLK1 inhibition by BI 6727 (volasertib) in 
LN-229 cells (FOCAD+/+) with stable FOCAD or control knockdown. a FOCAD levels were 
determined by Western blot analysis in control LN-229 cells stably transduced with a non-
targeted shRNA (control shRNA) at different time points after release from G1/S or M phase 
blockade by double thymidine or nocodazole treatment. FOCAD levels peaked 8-10 h after 
release from G1/S and 24 h after release from M phase blockade at the entry to mitosis. 
Histone H3 phosphorylation at serine 10 (pHH3(S10)) served as a mitotic marker and 
GAPDH as loading control. b Cell cycle progression of LN-229 cells with stable FOCAD 
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knockdown (FOCAD shRNA), control knockdown (control shRNA), and FOCAD re-
expression after FOCAD knockdown (FOCAD shRNA + rescue) stained with propidium 
iodide was analyzed by flow cytometry at several time points after release from G1/S 
blockade. In typical examples of DNA content histograms, arrows indicate accelerated cell 
cycle progression through G2/M phase, i.e. at 8-10 h after release from G1/S block when 
FOCAD expression was highest in control cells (a), in cells with reduced FOCAD expression 
compared to control cells, an effect diminished by FOCAD re-expression. c Quantification of 
2N DNA content histograms shown in (b) showing an acceleration in generating daughter 
cells with a 2N DNA content in cells with reduced FOCAD expression, which was rescued 
after FOCAD re-expression (mean ± SD of three independent experiments). Stable FOCAD 
knockdown was verified by Western blot analysis, vinculin (VCL) served as loading control. d 
Time points of mitotic entry of LN-229 FOCAD shRNA, control shRNA, and FOCAD shRNA + 
rescue cells after release from G1/S blockade were determined by Western blot analysis of 
cyclin B1 expression and serine 10 phosphorylation of histone H3 (pHH3(S10)). Earlier 
mitotic entry was detected in cells with reduced FOCAD expression compared to control 
cells, an effect reversed by FOCAD re-expression. GAPDH served as loading control. One 
representative experiment from a total of three experiments is shown. e, f FOCAD 
dependency of activating T210 phosphorylation of the cell cycle and mitotic entry regulator 
PLK1 were determined in LN-229 FOCAD shRNA, control shRNA, and FOCAD shRNA + 
rescue cells by Western blot analysis at 8 h after release from G1/S blockade (e) when 
FOCAD expression was high in control cells as shown in (a). Densitometric quantification of 
Western blot analysis shown in (e) detecting a significantly increased relative PLK1 
phosphorylation at T210 in cells with reduced FOCAD expression compared to control cells 
(mean ± SD of three independent experiments) (f). g FOCAD-dependent sensitivity to PLK1 
inhibitor BI 6727 was evaluated by assaying the viability of LN-229 FOCAD shRNA, control 
shRNA, and FOCAD shRNA + rescue cells after 48 h of inhibitor incubation time. Cells with 
reduced FOCAD expression showed a significantly decreased viability after PLK1 inhibition 
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compared to control cells (mean ± SD of three independent experiments performed in 
triplicate). *, p < 0.05 (Student’s t test). 
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